** Shares of Inari Medical NARI.O rise ~21% premarket to $78.50 premarket

** Larger rival Stryker Corp SYK.N late on Monday agreed to buy NARI in an all-cash deal worth $4.9 billion

** The deal for NARI, which makes devices that treat patients with venous diseases, bolsters Stryker's efforts to expand its offerings to treat venous thromboembolism, a condition where a blood clot forms in a vein, and other vascular diseases

** As part of the deal, which was first reported by Reuters, Stryker will pay $80 per share for Inari

** Up to last close, NARI stock has gained ~2% over the past 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))